Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × adavosertib × Gynecologic × Clear all

Phase

Phase 2 6 Phase 1 3 Phase EARLY_PHASE1 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1 Sarcoma 1 Gynecologic 1 Gastrointestinal 1 CNS 1

Conditions

Uterine Cervical Neoplasms 1

Interventions

Carboplatin 61 Paclitaxel 48 pembrolizumab 44 Cyclophosphamide 28 Cisplatin 22 Bevacizumab 22 Nivolumab 19 fludarabine 15 Topotecan 14 liposomal doxorubicin 13 olaparib 12 aldesleukin 12 Gemcitabine 12 Interleukin-2 11 Filgrastim 11 durvalumab 10 Peripheral Blood Stem Cell Transplantation 9 Docetaxel 9 Taxes 8 fludarabine phosphate 7 epacadostat 7 Specimen Handling 7 Ipilimumab 7 niraparib 6 lenvatinib 6 Magnetic Resonance Spectroscopy 6 Drug Therapy 6 Doxorubicin 6 Biopsy 6 toripalimab 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01076400 2023-09-18

MK-1775-008

Merck Sharp & Dohme LLC

Phase 1/2 Terminated

7 enrolled 6 charts

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡